New chemo combo aims to stop esophageal cancer from coming back

NCT ID NCT03110926

Ongoing Disease control Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This phase II trial is testing whether giving a chemotherapy combination called mFOLFOX6 before the usual chemoradiation and surgery can help prevent esophageal cancer from returning. The study involves 40 adults with locally advanced esophageal cancer that can be surgically removed. Researchers are measuring how many patients remain cancer-free after two years and checking for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mFOLFOX6 (a combination of chemotherapy drugs: oxaliplatin, leucovorin, and 5-fluorouracil)
What this could lead to: If successful, this approach could lower the chance of cancer returning after standard treatment for locally advanced esophageal cancer.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. Chemotherapy can cause significant side effects, and the added benefit over standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma of esophagus esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CARCINOMA

Contacts and locations

Locations

University of Rochester

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.